ライフサイエンスコーパス: invasive pulmonary aspergillosis

1 possible, and the remaining 165 patients no invasive pulmonary aspergillosis.

2 drugs, and is avirulent in a murine model of invasive pulmonary aspergillosis.

3 ematopoietic cell transplant recipients with invasive pulmonary aspergillosis.

4 y avirulent in two distinct murine models of invasive pulmonary aspergillosis.

5 e models of haematogenously disseminated and invasive pulmonary aspergillosis.

6 us infection in vitro and in mouse models of invasive pulmonary aspergillosis.

7 yene may be antagonistic in the treatment of invasive pulmonary aspergillosis.

8 ions of lung tissue recovered from mice with invasive pulmonary aspergillosis.

9 istance of A. terreus to AmB in experimental invasive pulmonary aspergillosis.

10 ay represent a new strategy for treatment of invasive pulmonary aspergillosis.

11 id-treated animals against subsequent lethal invasive pulmonary aspergillosis.

12 ha is an important proximal signal in murine invasive pulmonary aspergillosis.

13 tal cohort (n = 524), 79 patients had proven invasive pulmonary aspergillosis (15.1%).

14 Incidences of invasive pulmonary aspergillosis, an infection caused pr

15 p. was recovered as the etiological agent of invasive pulmonary aspergillosis and had reduced in vitr

16 are unexplored targets for the treatment of invasive pulmonary aspergillosis and may potentiate both

17 Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship be

18 idence that the inflammatory response during invasive pulmonary aspergillosis, and in particular the

19 This is particularly true for invasive pulmonary aspergillosis, as so far, sources of

20 depletion of neutrophils, animals developed invasive pulmonary aspergillosis, associated with delaye

21 pulmonary aspergillosis, two each with acute invasive pulmonary aspergillosis, chronic necrotizing pu

22 CalA antibody improves survival of mice with invasive pulmonary aspergillosis, demonstrating the pote

23 In invasive pulmonary aspergillosis, direct invasion and oc

24 inophil recruitment in neutropenic mice with invasive pulmonary aspergillosis (IA).

25 By use of a model of invasive pulmonary aspergillosis in corticosteroid-treat

26 ergillus respiratory tract colonization from invasive pulmonary aspergillosis in critically ill patie

27 s fumigatus is an important pathogen causing invasive pulmonary aspergillosis in immunocompromised pa

28 nhanced fungal clearance during experimental invasive pulmonary aspergillosis in neutropenic mice.

29 le in simultaneous treatment of experimental invasive pulmonary aspergillosis in persistently neutrop

30 nd-generation triazole, against experimental invasive pulmonary aspergillosis in persistently neutrop

31 inate Aspergillus colonization from putative invasive pulmonary aspergillosis in this patient group.

32 Risk factors for invasive pulmonary aspergillosis (IPA) after kidney tran

33 e prognostic factors and optimal therapy for invasive pulmonary aspergillosis (IPA) after kidney tran

34 eolar lavage (BAL) fluid in the diagnosis of invasive pulmonary aspergillosis (IPA) among solid-organ

35 f antifungal therapy on an LFD developed for invasive pulmonary aspergillosis (IPA) detection.

36 Invasive pulmonary aspergillosis (IPA) is a frequently f

37 Invasive pulmonary aspergillosis (IPA) is a life-threate

38 Invasive pulmonary aspergillosis (IPA) is a significant

39 damage due to unresolved inflammation during invasive pulmonary aspergillosis (IPA) is associated wit

40 Invasive pulmonary aspergillosis (IPA) is frequent and o

41 Invasive pulmonary aspergillosis (IPA) is often a lethal

42 Invasive pulmonary aspergillosis (IPA) is one of the maj

43 identification of the causative organism in invasive pulmonary aspergillosis (IPA) is recommended.

44 Invasive pulmonary aspergillosis (IPA) is the most commo

45 Diagnosis of invasive pulmonary aspergillosis (IPA) remains a major c

46 Invasive pulmonary aspergillosis (IPA) remains an import

47 ught to contribute to therapeutic failure in invasive pulmonary aspergillosis (IPA).

48 idered the gold standard test for diagnosing invasive pulmonary aspergillosis (IPA).

49 of Axl in antifungal immunity in a model of invasive pulmonary aspergillosis (IPA).

50 e is a first-line agent for the treatment of invasive pulmonary aspergillosis (IPA).

51 amples may facilitate the early diagnosis of invasive pulmonary aspergillosis (IPA).

52 ed for evaluation of patients with suspected invasive pulmonary aspergillosis (IPA).

53 pharmacodynamics of caspofungin (CAS) during invasive pulmonary aspergillosis (IPA).

54 Invasive pulmonary aspergillosis is a common and devasta

55 Invasive pulmonary aspergillosis is a devastating compli

56 Invasive pulmonary aspergillosis is a devastating compli

57 Invasive pulmonary aspergillosis is a leading cause of i

58 Invasive pulmonary aspergillosis is acquired through inh

59 Invasive pulmonary aspergillosis is an emerging devastat

60 Invasive pulmonary aspergillosis is an important cause o

61 influx of mononuclear cells into the lung in invasive pulmonary aspergillosis is in part mediated by

62 l effectors, and antifungal drug therapy for invasive pulmonary aspergillosis may be further understo

63 burden, and in situ angiogenesis in a murine invasive pulmonary aspergillosis model.

64 ppo-silenced mutant was hypervirulent in the invasive pulmonary aspergillosis murine model system and

65 ion in fungal lung burdens in a rat model of invasive pulmonary aspergillosis (p<0.05) compared to tr

66 e is unlikely to serve as an S source during invasive pulmonary aspergillosis since a sulfate transpo

67 Invasive pulmonary aspergillosis was an independent risk

68 Invasive pulmonary aspergillosis was defined according t

69 Probable or proven invasive pulmonary aspergillosis was diagnosed in 14% of